PMID- 34788923
OWN - NLM
STAT- MEDLINE
DCOM- 20211119
LR  - 20211123
IS  - 0253-2727 (Print)
IS  - 2707-9740 (Electronic)
IS  - 0253-2727 (Linking)
VI  - 42
IP  - 10
DP  - 2021 Oct 14
TI  - [Comparison of four prognostic scoring system in patients with early asymptomatic 
      chronic lymphocytic leukemia patients].
PG  - 834-839
LID - 10.3760/cma.j.issn.0253-2727.2021.10.007 [doi]
AB  - Objective: To compare the prognostic value of four prognostic models in 
      predicting time to first treatment (TTFT) in patients with Binet A Chinese 
      chronic lymphocytic leukemia (CLL) . Methods: This retrospective analysis 
      included one hundred and ten patients with Binet A CLL, initially diagnosed in 
      the First Affiliated Hospital of Nanjing Medical University (Pukou CLL center) 
      from June 2009 to January 2020. Risk stratification was conducted according to 
      IPS-E, CLL-IPI, CLL1-PM, and Barcelona-Brno prognostic models. Results: Among 110 
      patients with Binet A CLL patients, the median age was 58 (25-84) years. The 
      median follow-up time was 35 (4-189) months, and 57 (51.8%) patients met the 
      indication for treatment due to symptomatic disease progression during follow-up. 
      Log-rank analysis of nine variables was conducted involving age, Rai stage, 
      absolute lymphocyte count (ALC) , lymph node size, lymphocyte doubling time (LDT) 
      , beta(2)-Microglobulin, IGHV status, TP53, and Del (11q) . Additionally, Rai Ⅰ-Ⅲ, 
      ALC>15x10(9)/L, palpable lymph node size >/=1cm, beta(2)-Microglobulin>3.5 mg/L, 
      unmutated IGHV, TP53 mutation or deletion, and 11q deletion were independent risk 
      factors of TTFT. Predictive value of each model was assessed by Harrel C-index 
      and Akaike information criterion (AIC) with CLL1-PM (C-index=0.736, AIC=777) , 
      followed by CLL-IPI (C-index=0.722, AIC=933) , IPS-E (C-index=0.683, AIC=1004) , 
      and Barcelona-Brno prognostic model (C-index=0.663, AIC=986) . Conclusion: All 
      four prognostic models effectively predicted TTFT. IPS-E might be an ideal model 
      to guide clinical surveillance because of its easy accessibility and low expenses 
      in routine clinical practice. Therefore, for patients receiving fluorescence in 
      situ hybridization (FISH) and next-generation sequencing (NGS) examination at 
      diagnosis, CLL-IPI or CLL1-PM could be applied to evaluate their prognosis more 
      comprehensively.
FAU - Sha, Y Q
AU  - Sha YQ
AD  - Department of Hematology, the First Affiliated Hospital of Nanjing Medical 
      University, Jiangsu Province Hospital, Nanjing 210029, China Pukou CLL Center, 
      Pukou Division of Jiangsu Province Hospital, Nanjing 211800, China.
FAU - Shen, H
AU  - Shen H
AD  - Department of Hematology, the First Affiliated Hospital of Nanjing Medical 
      University, Jiangsu Province Hospital, Nanjing 210029, China Pukou CLL Center, 
      Pukou Division of Jiangsu Province Hospital, Nanjing 211800, China.
FAU - Wu, W
AU  - Wu W
AD  - Department of Hematology, the First Affiliated Hospital of Nanjing Medical 
      University, Jiangsu Province Hospital, Nanjing 210029, China Pukou CLL Center, 
      Pukou Division of Jiangsu Province Hospital, Nanjing 211800, China.
FAU - Xia, Y
AU  - Xia Y
AD  - Department of Hematology, the First Affiliated Hospital of Nanjing Medical 
      University, Jiangsu Province Hospital, Nanjing 210029, China Pukou CLL Center, 
      Pukou Division of Jiangsu Province Hospital, Nanjing 211800, China.
FAU - Miao, Y
AU  - Miao Y
AD  - Department of Hematology, the First Affiliated Hospital of Nanjing Medical 
      University, Jiangsu Province Hospital, Nanjing 210029, China Pukou CLL Center, 
      Pukou Division of Jiangsu Province Hospital, Nanjing 211800, China.
FAU - Cao, L
AU  - Cao L
AD  - Department of Hematology, the First Affiliated Hospital of Nanjing Medical 
      University, Jiangsu Province Hospital, Nanjing 210029, China Pukou CLL Center, 
      Pukou Division of Jiangsu Province Hospital, Nanjing 211800, China.
FAU - Wang, L
AU  - Wang L
AD  - Department of Hematology, the First Affiliated Hospital of Nanjing Medical 
      University, Jiangsu Province Hospital, Nanjing 210029, China Pukou CLL Center, 
      Pukou Division of Jiangsu Province Hospital, Nanjing 211800, China.
FAU - Fan, L
AU  - Fan L
AD  - Department of Hematology, the First Affiliated Hospital of Nanjing Medical 
      University, Jiangsu Province Hospital, Nanjing 210029, China Pukou CLL Center, 
      Pukou Division of Jiangsu Province Hospital, Nanjing 211800, China.
FAU - Xu, W
AU  - Xu W
AD  - Department of Hematology, the First Affiliated Hospital of Nanjing Medical 
      University, Jiangsu Province Hospital, Nanjing 210029, China Pukou CLL Center, 
      Pukou Division of Jiangsu Province Hospital, Nanjing 211800, China.
FAU - Li, J Y
AU  - Li JY
AD  - Department of Hematology, the First Affiliated Hospital of Nanjing Medical 
      University, Jiangsu Province Hospital, Nanjing 210029, China Pukou CLL Center, 
      Pukou Division of Jiangsu Province Hospital, Nanjing 211800, China.
FAU - Zhu, H Y
AU  - Zhu HY
AD  - Department of Hematology, the First Affiliated Hospital of Nanjing Medical 
      University, Jiangsu Province Hospital, Nanjing 210029, China Pukou CLL Center, 
      Pukou Division of Jiangsu Province Hospital, Nanjing 211800, China.
LA  - chi
GR  - 82170166, 81970146/National Natural Science Foundation of China/
GR  - 81720108002/National Science Foundation of China International Cooperation and 
      Exchange Program/
GR  - 2018ZX09734007/National Science and Technology Major Project/
GR  - WSN-001/Six Talent Peaks Project in Jiangsu Province, 2019/
PT  - Journal Article
PL  - China
TA  - Zhonghua Xue Ye Xue Za Zhi
JT  - Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi
JID - 8212398
SB  - IM
MH  - Humans
MH  - In Situ Hybridization, Fluorescence
MH  - *Leukemia, Lymphocytic, Chronic, B-Cell/diagnosis
MH  - Middle Aged
MH  - Prognosis
MH  - Retrospective Studies
MH  - Survival Rate
PMC - PMC8607014
OTO - NOTNLM
OT  - Leukemia, lymphocytic, chronic
OT  - Prognosis
EDAT- 2021/11/18 06:00
MHDA- 2021/11/20 06:00
PMCR- 2021/10/01
CRDT- 2021/11/17 21:14
PHST- 2021/11/17 21:14 [entrez]
PHST- 2021/11/18 06:00 [pubmed]
PHST- 2021/11/20 06:00 [medline]
PHST- 2021/10/01 00:00 [pmc-release]
AID - cjh-42-10-834 [pii]
AID - 10.3760/cma.j.issn.0253-2727.2021.10.007 [doi]
PST - ppublish
SO  - Zhonghua Xue Ye Xue Za Zhi. 2021 Oct 14;42(10):834-839. doi: 
      10.3760/cma.j.issn.0253-2727.2021.10.007.